Given that HMGCR is highly expressed in most cancers and exhibits distinct prognostic significance across different cancer types, it can serve as a predictive marker and novel therapeutic target for specific tumors with markedly increased cholesterol synthesis, such as prostate cancer, gastric cancer, colorectal cancer, and breast cancer. This evidence concerns the gene HMGCR and Familial prostate cancer.